BIBF 1120 and angiogenesis inhibition Carlos Gil Ferreira
Better lung cancer treatments Marianne Nicolson
BIBF 1120 (Vargatef) in lung cancer Lucio Crinò
Angiokinase inhibitors in lung cancer Marianne Nicolson
BIBF 1120* Mode of Action
Personalising cancer care and the future of cancer treatments John Heymach
Personalised medicine and the future of oncology treatment Gerd Munzert
EGFR Mode of Action
The latest data for BIBF 1120* in ovarian cancer Marianne Nicolson
Afatinib* (compound code BIBW 2992) Mode of Action
Lung cancer and afatinib Federico Cappuzzo
The evolution of lung cancer care Boehringer Ingelheim
Changing the outlook for personalised cancer therapy Boehringer Ingelheim
Targeted cancer therapies
Volasertib* and Polo-like kinase (Plk) inhibition
Angiokinase Inhibition and Nintedanib (BIBF 1120)*
ErbB-Family Blockade and afatinib*
BIBF 1120 anticancer agent
Afatinib* Backgrounder
Resistance to EGFR TKIs
Irreversible binding of afatinib
Mode of Action BIBF 1120* slide kit
Mutation detection with Quantitative Real Time PCR (Q-PCR)
Mode of action afatinib* slide kit
Boehringer Ingelheim and the search for new targeted cancer treatments
BIBF 1120 (Vargatef) slide kit
Afatinib (BIBW 2992) slide kit
Could new cancer targets change the outlook for personalised medicine?
Webcast South Korea, the evolution of lung cancer care
Source for healthcare professionals: www.inoncology.com* BIBF 1120, BIBW 2992 and BI 6727 are investigational compounds. Their safety and efficacy have not yet been fully established.